Anjali S Advani1, William Tse2, Hong Li3, Xuefei Jia3, Paul Elson3, Brenda Cooper4, Francis Ali-Osman5, Jino Park6, Arati V Rao7, David A Rizzieri8, Eunice S Wang9, Claudiu V Cotta10, Matt Kalaycio11, Ronald M Sobecks11, Basel Rouphail11, Jaroslaw P Maciejewski12, Jaime Fensterl11, Jennifer S Carew13, Bethany Foster11, Mary Lynn Rush11, Barbara Tripp11, Donna Adams5, Donna Corrigan11, Elizabeth A Griffiths9, Mikkael A Sekeres11. 1. Department of Hematology/ Oncology, Cleveland Clinic Taussig Cancer Institute Leukemia Program, Cleveland, OH. Electronic address: advania@ccf.org. 2. Department of Hematology/ Oncology, Metro Health, Cleveland, OH. 3. Cleveland Clinic, Quantitative Health Sciences, Cleveland, OH. 4. Department of Hematology/ Oncology, University Hospitals of Cleveland, Cleveland, OH. 5. Department of Hematology/ Oncology, Duke University, Durham, NC. 6. James Graham Brown Cancer Center, University of Louisville School of Medicine, Louisville, KY. 7. Duke Cancer Institute, Duke University, Durham, NC; Current affiliation: PACT Pharma, South San Francisco, CA. 8. Duke Cancer Institute, Duke University, Durham, NC. 9. Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY. 10. Department of Pathology, Cleveland Clinic, Cleveland, OH. 11. Department of Hematology/ Oncology, Cleveland Clinic Taussig Cancer Institute Leukemia Program, Cleveland, OH. 12. Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH. 13. University of Arizona Cancer Center, Leon Levy Cancer Center, Tuscon, AZ.
Abstract
INTRODUCTION: Adults with acute myeloid leukemia (AML) have a high rate of remission; however, more than 50% relapse. C-kit is expressed in approximately 60% of patients with de novo AML and represents a potential therapeutic target. MATERIALS AND METHODS: Patients with newly diagnosed AML received 12 months of imatinib mesylate as maintenance therapy after the completion of post-remission therapy. The primary objective was to determine whether this approach improved progression-free survival (defined as no relapse and no death) compared with historical controls. RESULTS: The median progression-free survival of patients < 60 years of age was 52.1 months (historical control, 13 months) and for patients ≥ 60 years of age was 10.7 months (historical control, 8 months). The median level of AF1q expression was high (9.59), and 84% of patients had moderate or high levels of drug-resistance factors. CONCLUSIONS: Imatinib maintenance therapy may improve the outcome of newly diagnosed patients with AML who are < 60 years of age.
INTRODUCTION: Adults with acute myeloid leukemia (AML) have a high rate of remission; however, more than 50% relapse. C-kit is expressed in approximately 60% of patients with de novo AML and represents a potential therapeutic target. MATERIALS AND METHODS: Patients with newly diagnosed AML received 12 months of imatinib mesylate as maintenance therapy after the completion of post-remission therapy. The primary objective was to determine whether this approach improved progression-free survival (defined as no relapse and no death) compared with historical controls. RESULTS: The median progression-free survival of patients < 60 years of age was 52.1 months (historical control, 13 months) and for patients ≥ 60 years of age was 10.7 months (historical control, 8 months). The median level of AF1q expression was high (9.59), and 84% of patients had moderate or high levels of drug-resistance factors. CONCLUSIONS: Imatinib maintenance therapy may improve the outcome of newly diagnosed patients with AML who are < 60 years of age.
Authors: Øystein Bruserud; Galina Tsykunova; Maria Hernandez-Valladares; Hakon Reikvam; Tor Henrik Anderson Tvedt Journal: Pharmaceuticals (Basel) Date: 2021-05-02